| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg | |||
| Other Sizes |
| Targets |
The primary target of F-Chemotactic peptide is the formyl peptide receptor (FPR), specifically FPR1. FPRs are G protein-coupled receptors that play a key role in the innate immune response by mediating the chemotaxis of neutrophils and other leukocytes to sites of infection or inflammation. By acting as a potent agonist, F-Chemotactic peptide activates FPR1, triggering downstream signaling pathways that lead to neutrophil migration and activation.
|
|---|---|
| ln Vitro |
In vitro, F-Chemotactic peptide is a potent agonist of the formyl peptide receptor (FPR). It has high affinity for FPR1 with a Kd of approximately 2.2 nM. The peptide is a chemoattractant for human neutrophils, inducing cell migration and superoxide production. Its oxidative stability, due to the replacement of methionine with norleucine, makes it more reliable for sustained FPR1 activation compared to fMLP.
|
| ln Vivo |
In vivo, F-Chemotactic peptide is used to study neutrophil chemotaxis and the inflammatory response. As a potent FPR agonist, it can be administered to animal models to induce neutrophil migration to sites of injection. This allows researchers to investigate the mechanisms of inflammation and the role of FPRs in the immune response. Its high affinity and stability make it a valuable tool for in vivo studies.
|
| Enzyme Assay |
In vitro receptor binding studies for F-Chemotactic peptide measure its affinity for FPR1. Radioligand competition assays are performed using membrane preparations from cells expressing FPR1. The peptide competes with a labeled ligand, such as [³H]fMLP, for binding, and the Kd or IC₅₀ values are determined. These assays confirm its high affinity for FPR1.
|
| Cell Assay |
In vitro cell-based assays for F-Chemotactic peptide evaluate its ability to induce neutrophil chemotaxis and activation. Neutrophils are isolated from human blood and placed in a chemotaxis chamber. The peptide is added to the lower chamber, and the migration of neutrophils is measured. Superoxide production is assessed using assays such as the cytochrome c reduction assay. These assays confirm its activity as a potent FPR agonist.
|
| Animal Protocol |
In vivo animal studies for F-Chemotactic peptide are conducted to study inflammation and neutrophil migration. The peptide is injected into the peritoneum or other tissues of rodents, and the influx of neutrophils is measured. The compound's ability to induce an inflammatory response is assessed by counting the number of neutrophils in the peritoneal lavage fluid or by measuring markers of inflammation. These studies help to characterize the role of FPRs in the immune response.
|
| ADME/Pharmacokinetics |
The pharmacokinetic properties of F-Chemotactic peptide have been characterized in preclinical studies. Its molecular weight is 824.0 g/mol. The compound is soluble in DMSO. For research use, it is stored as a solid powder in a dry, dark environment at 0-4°C for short-term storage or at -20°C for long-term storage. Further details on its half-life and bioavailability are available from the primary research literature.
|
| Toxicity/Toxicokinetics |
The toxicity profile of F-Chemotactic peptide has not been extensively detailed in the available literature. It is classified for research use only and not for human consumption. As a potent activator of the immune system, its potential side effects may include excessive inflammation. Standard safety precautions for handling peptides should be followed.
|
| References | |
| Additional Infomation |
Additional information: F-Chemotactic peptide is also known as N-Formyl-Nle-Leu-Phe-Nle-Tyr-Lys and F-Peptide. Its sequence is For-Nle-Leu-Phe-Nle-Tyr-Lys. The compound is a potent FPR agonist with high affinity and oxidative stability. It is used as a research tool to study neutrophil chemotaxis and inflammation. This product is for research use only and is not approved for clinical or therapeutic applications.
|
| Molecular Formula |
C43H65N7O9
|
|---|---|
| Molecular Weight |
824.03
|
| Exact Mass |
823.484
|
| CAS # |
71901-21-8
|
| Related CAS # |
N-Formyl-Nle-Leu-Phe-Nle-Tyr-Lys TFA;2918767-97-0
|
| PubChem CID |
123875
|
| Appearance |
White to off-white solid powder
|
| Density |
1.182 g/cm3
|
| Boiling Point |
1183.3ºC at 760 mmHg
|
| Flash Point |
669.4ºC
|
| Index of Refraction |
1.553
|
| LogP |
6.037
|
| Hydrogen Bond Donor Count |
9
|
| Hydrogen Bond Acceptor Count |
10
|
| Rotatable Bond Count |
28
|
| Heavy Atom Count |
59
|
| Complexity |
1300
|
| Defined Atom Stereocenter Count |
6
|
| SMILES |
CCCC[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCC)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CCCCN)C(=O)O)NC=O
|
| InChi Key |
XZMLMTGOWVWIRV-DUGSHLAESA-N
|
| InChi Code |
InChI=1S/C43H65N7O9/c1-5-7-16-32(45-27-51)38(53)48-35(24-28(3)4)40(55)50-36(25-29-14-10-9-11-15-29)41(56)46-33(17-8-6-2)39(54)49-37(26-30-19-21-31(52)22-20-30)42(57)47-34(43(58)59)18-12-13-23-44/h9-11,14-15,19-22,27-28,32-37,52H,5-8,12-13,16-18,23-26,44H2,1-4H3,(H,45,51)(H,46,56)(H,47,57)(H,48,53)(H,49,54)(H,50,55)(H,58,59)/t32-,33-,34-,35-,36-,37-/m0/s1
|
| Chemical Name |
((S)-2-((S)-2-((S)-2-((S)-2-formamidohexanamido)-4-methylpentanamido)-3-phenylpropanamido)hexanoyl)-L-tyrosyl-L-lysine
|
| Synonyms |
F-Chemotactic peptide Cho-nle-leu-phe-nle-tyr-lys N-Formyl hexapeptideFNLPNTL F-PeptideFNLELFNLRYK
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~16.67 mg/mL (~20.23 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.2135 mL | 6.0677 mL | 12.1355 mL | |
| 5 mM | 0.2427 mL | 1.2135 mL | 2.4271 mL | |
| 10 mM | 0.1214 mL | 0.6068 mL | 1.2135 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT05040867 | UNKNOWN STATUS | Other: Physical exercise program | Autonomic Imbalance Breast Cancer Cardiotoxicity |
GO fit Lab- Ingesport | 2021-09-13 | Not Applicable |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
